Press Releases RedHill Biopharma Ltd. Deutsche Boerse AG

Equities

2RH0

US7574682024

Delayed Deutsche Boerse AG Other stock markets 07:10:55 16/07/2024 BST			5-day change	1st Jan Change
0.3205 ^EUR	+1.10%		+4.57%	-74.76%

07-09	Redhill Biopharma Ltd. Terminates License Agreement for Aemcolo	CI
06-06	RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RedHill Biopharma Terminates License Agreement for Aemcolo	07-10	AQ
RedHill Biopharma : Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040 - Form 6-K	06-03	PU
RedHill Biopharma : Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035 - Form 6-K	05-06	PU
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035	05-06	PR
RedHill Biopharma : Announces First Patient Enrolled in U.S. Government- Supported COVID-19 Study - Form 6-K	04-24	PU
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights	04-09	AQ
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price	04-03	AQ
RedHill Biopharma : Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs - Form 6-K	03-05	PU
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs	03-05	PR
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis, New Publication	02-21	AQ
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication	02-20	PR
Nasdaq Stocks Under $1 to Watch Now! VTAK, IVP, ONCO, AKTS, RDHL	01-31	AQ
RedHill Biopharma Announces $8 Million Registered Direct Offering	01-26	AQ
RedHill Announces New USPTO Patent Grant for Talicia for H. pylori Treatment Through 2042	01-26	AQ
RedHill Biopharma : and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola - Form 6-K	12-20	PU
RedHill Biopharma : Exercise of Existing Warrants Resulting in $4 Million Proceeds to the Company - Form 6-K	12-06	PU
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study	12-04	PR
Small Cap Companies Spearheading Innovation in the Biopharma Healthcare Sector" INBS, RDHL, CDIO, VTAK, DNA	11-30	AQ
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034	11-27	PR
RedHill Biopharma Announces the Transfer of its Listing to the Nasdaq Capital Market	11-15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases RedHill Biopharma Ltd. Deutsche Boerse AG

Equities

2RH0

US7574682024

Press Releases

Filters